Two West Coast firms have teamed up to create the first graphene-activated biosensor that can be mass-produced. San Diego-based Nanomedical Diagnostics and Medford, Oregon, headquartered Rogue Valley Microdevices are delivering the compact AGILE R100 to pharmaceutical and biotherapeutics companies to help them discover new drugs for treating diseases like diabetes.
A biosensor is an analytical tool that converts a biological response into an electrical signal that can measure the concentration and other parameters of substances at a molecular level. Graphene, because of its superior binding and conductivity properties, is an ideal replacement for traditionally used silicon chips in Nanomedical’s Field Effect Biosensing technology.
“Now, as quoted in Newelectronics.co.uk, Nanomedical Diagnostics CEO Ross Bundy says the graphene biosensor can be produced in mass numbers: ‘Rogue Valley Microdevices has been a true partner in developing a viable large-scale fabrication process for our AGILE biosensor chips. The ability to manufacture graphene biosensors at scale will enable us to create significant cost reductions for many life science and healthcare applications, as well as introduce game-changing capabilities that have never been seen before.’”